MENU

Multi-diagnostic approaches for patient selection in immuno-oncology

C.E. Credits: P.A.C.E. CE Florida CE
Speaker

Abstract

The development of different classes of immunotherapies that target cancer cells continues to be a rapidly growing area of research. The development of diagnostic tests which can predict patient response to these therapies are crucial to the clinical success of an immunotherapy candidate. Checkpoint inhibitors are one class of immunotherapy that release the breaks on immune cells, enabling them to attack cancer cells. Several checkpoint inhibitors that target the PD-1/PD-L1 axis have been approved for a variety of tumor indications. In some tumor types, the efficacy of these agents has been linked to PD-L1 expression levels, leading to the approval of several PD-L1 IHC assays as companion diagnostics. Advances in clinical research and our understanding of the tumor microenvironment underscore the importance of new markers to assess immune infiltration and abnormal activity in cellular pathways, including DNA damage repair and DNA replication. Multiple biomarker assays and methodologies, beyond PD-L1 expression, are being explored for use in selecting patients for checkpoint inhibitor studies and will be reviewed in this presentation. In addition, biomarkers that could aid in patient selection for other types of immunotherapies will be discussed.

Learning Objectives:

1. Define the different classes of immunotherapy being developed for cancer treatment

2. Identify the utility and limitations of current biomarkers for the selection of patients for checkpoint inhibitor therapy

3. Compare/contrast methods and assays being used for biomarker analysis


Show Resources
You May Also Like
MAY 17, 2022 9:00 AM PDT
MAY 17, 2022 9:00 AM PDT
Date: May 17, 2022 Time: 9:00am (PDT), 12:00pm (EDT), 8:00pm (CEST) Gene therapeutics have great potential to treat many severe diseases in an unprecedented, targeted manner. The biopharmace...
AUG 10, 2022 10:00 AM PDT
AUG 10, 2022 10:00 AM PDT
Date: August 10, 2022 Time: 10:00am PDT, 1:00pm EDT The global pandemic has increased focus and scrutiny on molecular diagnostic assay development, resulting in a need for assays that provid...
OCT 12, 2022 8:00 AM PDT
OCT 12, 2022 8:00 AM PDT
First Broadcast: Date: October 12, 2022 Time: 8:00am PDT, 11:00am EDT Second Broadcast: Date: October 12, 2022 Time: 9:00am SGT The new Embedded CryoSPARC Live, now fully integrated with t...
JUN 21, 2022 6:00 AM PDT
JUN 21, 2022 6:00 AM PDT
Date: June 21, 2022 Time: 6:00am (PDT), 9:00am (EDT), 3:00pm (CEST) The global understanding and practice of medicine is currently undergoing a revolutionary change. This shift to precision...
NOV 16, 2022 7:00 PM PST
C.E. CREDITS
NOV 16, 2022 7:00 PM PST
Date: November 16, 2022 Time: 2:00pm (AEST) Date: November 17, 2022 7:00pm (PST), 10:00pm (EST), 4:00am (CET) The growth in FDA-approved cell and gene therapy products for the treatment of d...
SEP 28, 2022 9:00 AM PDT
SEP 28, 2022 9:00 AM PDT
Date: September 28, 2022 Time: 9:00am (PDT), 12:00pm (EDT), 6:00pm (CEST) While COVID-19 continues to be the most pressing diagnostic focus for clinical laboratories, HIV remains a serious g...
Loading Comments...
Show Resources